SPRO Research and Charts

SPRO - Spero Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-06-30)

Last 2.90	Change ⇓ -0.04 (-1.36%)	Volume 1,153,841
	Open 2.99	High 3.00	Low 2.90

8EMA (Daily) 2.90	40EMA (Daily) 2.14	50EMA (Daily) 1.96	STO (Daily) 70.077	MACD Hist (Daily) -0.107
8EMA (Weekly) 2.368	40EMA (Weekly) 1.42	50EMA (Weekly) 1.39	STO (Weekly) 91.558	MACD Hist (Weekly) 0.507


Company Profile
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.